Malcolm et al. 2018: Ibogaine, Opioid Withdrawal & Craving Scores (n=50 Observational Study)

Definition

Definition: Malcolm B.J., Polanco M., & Barsuglia J.P. (2018) *Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine*, *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2018.1447175; PMID 29608409). Prospective-style observational scoring in n=50 participants with OUD during a week-long clinic detoxification protocol using ibogaine: ASI baseline characterization; COWS, SOWS, and BSCS at 48 h and 24 h pre-dose and 24 h and 48 h post-dose. At 48 hours post-ibogaine, authors report substantially lowered withdrawal/craving versus baseline—78% without objective clinical withdrawal signs, 79% minimal cravings, 68% subjective withdrawal in the mild range. Route = clinic oral ibogaine context (clinic setting named in author affiliations)—not psychoactive IV ibogaine infusion. Observational, not RCT; not a cure claim; not approved for any indication. Ibogaine is U.S. Schedule I. QTc/cardiac risk remains central (this paper is an outcomes/withdrawal-score report, not a cardiac-safety trial).

Short answer

Malcolm, Polanco, and Barsuglia’s 2018 Journal of Psychoactive Drugs observational study in 50 people with opioid use disorder found large short-term drops in COWS, SOWS, and craving scores after clinic ibogaine detoxification. Observational withdrawal scores are not controlled proof and not psychoactive IV ibogaine infusion evidence. Schedule I; screen for QTc risk.

Why this paper matters

Other well-known opioid use disorder observational studies include Brown & Alper 2018 (/blog/brown-alper-2018-ibogaine-oud), Noller 2018 (/blog/noller-2018-ibogaine-new-zealand), Mash 2018 (/blog/mash-2018-ibogaine-detox-frontiers), and Knuijver 2021 (/blog/knuijver-2021-ibogaine-qtc-safety). Malcolm 2018 adds a distinct, frequently cited n=50 COWS/SOWS/BSCS short-window detoxification dataset from a clinic protocol, using timed withdrawal scales rather than a retrospective survey. Next steps: /safety-and-screening → /apply.

For a retrospective survey of the same clinic program, see Davis et al. 2017 (/blog/davis-barsuglia-2017-ibogaine-survey).

What was studied

Methods (plain language)

Clinicians tracked standard opioid withdrawal and craving questionnaires before and after ibogaine during a structured detox week. When scores fall, that is meaningful acute pharmacology/clinic-process signal. Without randomization, expectancy, adjunct meds, and selection still confound “ibogaine alone did X.”

Key findings (no hype)

• Withdrawal and craving scores were significantly lower at 48 hours post-ibogaine versus baseline comparisons reported by the authors.
• Majority of participants no longer showed objective COWS-range clinical withdrawal signs at that snapshot.
• Craving ratings clustered toward minimal for most respondents at 48 hours.
• Authors explicitly say results warrant rigorous controlled trials—editorial pages should repeat that sentence, not delete it.
• Short observation window does not answer 6–12 month abstinence probability (see Brown/Noller/Davis durability-adjacent papers for longer views with their own biases).

Honest reading: Strong acute observational detox signal; weak causal certainty; zero license for “100% detox miracle” ads.

How it sits beside other OUD observationals

Cardiac safety gap in this paper

Malcolm 2018 is optimized for withdrawal psychometrics, not continuous QTc tables. Readers must still visit cardiac articles before any logistics (/blog/ibogaine-mortality-cardiac-risk, /blog/corkery-ibogaine-fatalities, /safety-and-screening). Clinic observation abroad ≠ approved U.S. clinic.

Route honesty & entity clarity

Clinic oral detox protocols ≠ physician-supervised psychoactive IV ibogaine infusion. Do not paste Malcolm’s 78%/79% figures into IV infusion ads as route-proof (/blog/ibogaine-oral-vs-iv; /what-is-ibogaine-infusion).

Limits and confounders

What this does NOT prove for IV ibogaine infusion

How to read the 78% / 79% / 68% figures

Allowed pattern: “In Malcolm et al. 2018’s observational n=50 clinic sample, authors reported that at 48 hours post-ibogaine, 78% lacked objective clinical withdrawal signs on COWS-framed assessment, 79% reported minimal cravings, and 68% had mild-range subjective withdrawal—findings that still require controlled replication and do not establish psychoactive IV ibogaine efficacy.”

Forbidden pattern: “Ibogaine has a 78% cure rate.” Percentages without method class, time window, and observational label are misleading.

Aftercare reminder

Even dramatic 48-hour score drops do not replace relapse-prevention planning, housing, and psychiatric follow-up (/blog/ibogaine-aftercare-integration). Brown/Noller longer follow-ups show trajectories can change after the acute window—another reason not to weaponize Malcolm’s snapshot as lifelong prognosis.

Next steps

Withdrawal-score hope is not a screening plan. Start here: /safety-and-screening → /apply for supervised IV ibogaine infusion questions.

FAQ

Which paper is this article about? Malcolm, Polanco & Barsuglia 2018, *J Psychoactive Drugs*, doi **10.1080/02791072.2018.1447175**, PMID **29608409**.

How is it different from other OUD studies? It reports timed COWS/SOWS/BSCS withdrawal and craving scores in 50 people around the dose, which is distinct from the longer-term outcome reports by Brown, Noller, and Mash.

Is it an RCT? No. Authors call for controlled trials.

What happened at 48 hours? Authors report large proportions with minimal objective withdrawal and craving on standard scales—observational snapshot only.

Was the route IV ibogaine? No—clinic oral ibogaine context; not psychoactive IV infusion proof.

Does this erase cardiac risk? No. Pair with QT/fatality articles.

Is ibogaine approved for medical use? No. Schedule I.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Malcolm B.J., Polanco M., Barsuglia J.P. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1447175. PMID: 29608409.
2. Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
3. Noller G.E. et al. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1310218.
4. Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
5. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Malcolm 2018 is an observational clinic oral detox scoring study—not a cure claim and not psychoactive IV ibogaine efficacy proof.